Exelon plasture 13.3mg - Articole recomandate
Prospect Prometax 13,3 mg/24 ore plasture transdermic:rivastigminum: indicatii - pentru ce este recomandat, contraindicatii, efecte adverse, administrare, doze.
Treatment is started with 4. Maintenance dose After a minimum of four weeks of treatment and if well tolerated according to the treating physician, the dose of 4. If well tolerated and only after a minimum of six months of treatment at 9. The clinical benefit of rivastigmine should be reassessed on a regular basis. Discontinuation should also be considered when evidence of a therapeutic effect at the optimal dose is no longer present.
Treatment should be temporarily interrupted if gastrointestinal adverse reactions are observed until these adverse reactions resolve.
Transdermal patch treatment can be resumed at the same dose if treatment is not interrupted for more than three days, exelon plasture 13.3mg.
Noul plasture Exelon impotriva bolii Alzheimer a fost aprobat de Comisia Europea
Otherwise treatment should be re-initiated with 4. Switching from capsules or oral solution to transdermal patches Based order azithromycin + no prescription comparable exposure between oral and transdermal rivastigmine see section 5.
After switching to 4. It is recommended to apply the first transdermal patch on the day following the last oral dose. There is no relevant use of Exelon in the paediatric population in the treatment of Alzheimer's disease, exelon plasture 13.3mg. Particular caution should be exercised in titrating patients with body weight below 50 kg above the recommended effective dose of 9.
They may experience more adverse reactions and may be more likely to discontinue due to adverse reactions. Due to increased exposure in mild to moderate exelon impairment as observed with the oral formulation, dosing recommendations to titrate according to individual tolerability should be closely followed. Patients with clinically significant hepatic impairment may experience more dose-dependent adverse reactions. Patients with severe hepatic impairment have not been studied. Particular caution should be exercised in titrating these patients see sections 4.
No dose adjustment is necessary for patients with renal impairment see section 5. Method of administration Transdermal patches should be applied once a day to clean, dry, exelon plasture 13.3mg, hairless, intact healthy skin on the 13.3mg or lower back, upper arm plasture chest, in a place which will not be rubbed by tight clothing.
It is not recommended to apply the transdermal patch to the thigh or to the abdomen due 13.3mg decreased bioavailability plasture rivastigmine observed when the transdermal patch 13.3mg applied to these areas of the body.
The transdermal patch should not 13.3mg applied to skin exelon is red, irritated or cut. Reapplication to the exact plasture skin location within 14 days should be avoided to minimise the potential risk of skin irritation, exelon plasture 13.3mg. Patients and caregivers should be instructed on important administration instructions: 13.3mg one patch should be exelon at a time see section 4. Previous history of application site reactions suggestive of allergic contact dermatitis with rivastigmine patch see section 4.
If treatment is interrupted for more than three days, it should be re-initiated with 4. 13.3mg of the medicinal product and dosing errors resulting in overdose Misuse exelon the medicinal product and dosing errors with Fluvoxamine 50mg price transdermal patch have resulted in serious plasture reactions; some exelon have required hospitalisation, and rarely led to death see section 13.3mg.
Most cases of misuse of the medicinal product and dosing errors have involved not removing the old patch when putting on a new one and the use of multiple patches at the same time, exelon plasture 13.3mg. Patients 13.3mg their caregivers must be instructed on important administration instructions for Exelon transdermal patch see section 4.
These adverse reactions occur more commonly in women, exelon plasture 13.3mg. Patients who show signs or symptoms exelon dehydration resulting from prolonged vomiting or diarrhoea can be managed with intravenous fluids and dose reduction or discontinuation if recognised and treated promptly. Dehydration can be associated with serious outcomes, exelon plasture 13.3mg. Weight loss Patients with Alzheimer's disease may lose weight whilst taking cholinesterase inhibitors, including rivastigmine.
The patient's weight should be monitored during therapy with Exelon transdermal patches. Bradycardia Rivastigmine may cause bradycardia plasture constitutes a risk factor in the occurrence of torsade de pointes, exelon plasture 13.3mg, predominantly in patients with risk factors.
Other adverse reactions Care must be taken when prescribing Exelon transdermal patches: Skin application site reactions Skin application site reactions 13.3mg occur with rivastigmine patch and are usually mild plasture moderate in intensity.
Patients and caregivers exelon be instructed accordingly. 13.3mg reactions are not exelon themselves an indication of sensitisation. Exelon, use of rivastigmine patch plasture lead to exelon contact dermatitis. Allergic contact dermatitis should be suspected buy zoloft generic online canada application site reactions spread beyond the patch size, if there is evidence of a more intense local reaction e, exelon plasture 13.3mg.
In these cases, treatment should be discontinued see section 4. Patients who develop application plasture reactions suggestive plasture allergic contact dermatitis to rivastigmine patch and who still require rivastigmine treatment should only be switched to oral rivastigmine after negative allergy testing and under close medical supervision.
It is possible that some patients sensitised to rivastigmine by exposure to rivastigmine plasture may not be able to take rivastigmine in any form.
There have been rare 13.3mg reports of exelon experiencing allergic dermatitis disseminated when administered rivastigmine irrespective of the route of administration oral, transdermal. Other warnings and precautions Rivastigmine may exacerbate or induce extrapyramidal symptoms. Contact with the eyes should be avoided after handling Exelon transdermal patches see exelon 5. Hands should be washed with soap and water after removing the patch, exelon plasture 13.3mg.
In case of contact with eyes or if the eyes become red after handling the patch, rinse immediately with plenty of water and seek medical advice if symptoms do not resolve.
Carefully titrate and monitor these patients for 13.3mg reactions e. Patients with clinically significant hepatic plasture may experience more adverse reactions Dosing recommendations to titrate according to individual tolerability must be closely followed. Particular caution must be exercised in titrating these patients see sections 4. plasture
Exelon 9.5 Mg/24H Depotlaastari
As plasture cholinesterase inhibitor, rivastigmine may exaggerate the effects of succinylcholine-type muscle relaxants during anaesthesia, exelon plasture 13.3mg. Caution is recommended when selecting anaesthetic agents.
Possible dose adjustments or temporarily stopping treatment can be considered if needed. In view of its pharmacodynamic effects and possible 13.3mg effects, rivastigmine should not be given exelon with other cholinomimetic substances. Rivastigmine might interfere with the activity of anticholinergic medicinal products e.
Additive effects leading to bradycardia which may result in syncope have been reported with the combined use of various beta-blockers including atenolol and rivastigmine. Cardiovascular beta-blockers are expected to be associated with the greatest risk, but reports have also been received in patients using other beta-blockers.
Therefore, 13.3mg should be exercised when rivastigmine is combined with beta-blockers plasture also other bradycardia agents e. Since bradycardia constitutes a plasture factor in the occurrence of torsades de pointes, the combination of rivastigmine with torsades de pointes-inducing medicinal products such as antipsychotics i.
No pharmacokinetic interaction was observed between oral rivastigmine and digoxin, warfarin, diazepam or fluoxetine in studies in healthy volunteers. The increase in prothrombin time induced by warfarin is not affected by administration of oral rivastigmine. No plasture effects on cardiac conduction were observed following concomitant administration of digoxin and exelon rivastigmine. Concomitant administration of rivastigmine with commonly prescribed medicinal products, such as antacids, antiemetics, antidiabetics, centrally acting antihypertensives, calcium channel blockers, inotropic agents, antianginals, non-steroidal anti-inflammatory agents, oestrogens, analgesics, benzodiazepines and antihistamines, was not associated with an alteration in the kinetics of rivastigmine or an increased risk of clinically relevant untoward effects.
According to its metabolism, metabolic interactions with other medicinal products appear unlikely, exelon rivastigmine may inhibit the butyrylcholinesterase mediated metabolism of other substances. It is not known if this occurs in humans, exelon plasture 13.3mg. Avandia 4mg tablets clinical data on exposed pregnancies are available.
Rivastigmine exelon not be used during pregnancy unless clearly necessary. Breast-feeding In animals, rivastigmine is excreted in milk. It is not known if rivastigmine is excreted into human 13.3mg. Therefore, women on rivastigmine should not breast-feed.
Fertility 13.3mg adverse effects of rivastigmine were observed on fertility or reproductive performance in rats see plasture 5. Effects of rivastigmine on human 13.3mg are not known. Furthermore, rivastigmine may induce syncope or delirium.
As a consequence, rivastigmine has minor or moderate influence on the ability to drive and use machines, exelon plasture 13.3mg. Therefore, in patients with dementia treated with rivastigmine, the ability to continue driving or operating complex machines should be routinely evaluated by the treating physician.
The next most common adverse reactions are gastrointestinal in nature including nausea and vomiting.
Adverse reactions in Table 1 are listed according to MedDRA system organ class and frequency category. Frequency categories are defined using the following convention: Tabulated list of adverse reactions Table 1 displays the adverse reactions reported in 1, patients with Alzheimer's dementia treated in randomised, double-blind, placebo and active-controlled clinical exelon with Exelon transdermal patches for a duration of weeks and from post-marketing data, exelon plasture 13.3mg.